Fibromyalgia: Clinical Trials

8 trials for Fibromyalgia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 8
Phase 31Terminated 1

Follow Fibromyalgia: new trials by email Literature Review of Fibromyalgia trials Research Report on Fibromyalgia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
iTBS-DCS in Fibromyalgia
D-Cycloserine, Placebo oral tablet, iTBS repetitive Transcranial Magnetic Stimulation (rTMS) - Fibromyalgia
Phase 2TerminatedUniversity of Calgary472022-08-292025-08-17
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia
Fremanezumab, Placebo - Fibromyalgia
Phase 2TerminatedTeva Branded Pharmaceutical Products R&D, Inc.1892019-07-312023-03-30
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Milnacipran, Placebo - Primary Fibromyalgia
Phase 2TerminatedForest Laboratories1162011-04-302019-05-14
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Milnacipran - Primary Fibromyalgia
Phase 2TerminatedForest Laboratories572011-04-012013-09-30
Pramipexole ER vs. Placebo in Fibromyalgia
pramipexole ER, placebo - Fibromyalgia
Phase 2TerminatedBoehringer Ingelheim612008-07-012014-06-09
A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia
Desvenlafaxine Sustained Release (DVS SR), Lyrica® (Pregabalin), Placebo - Fibromyalgia
Phase 2TerminatedWyeth is now a wholly owned subsidiary of Pfizer1252008-06-012013-02-25
Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
placebo, AGN 203818 - Fibromyalgia
Phase 2TerminatedAllergan2112007-03-012015-09-07
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
DVS-233 - Fibromyalgia
Phase 2 / Phase 3TerminatedWyeth is now a wholly owned subsidiary of Pfizer10502006-08-012007-12-05

Narrower conditions

Fatigue (2)  ·  Pain (2)

Broader conditions

Muscular Diseases (8)  ·  Musculoskeletal Diseases (8)  ·  Nervous System Diseases (8)  ·  Neuromuscular Diseases (8)  ·  Rheumatic Diseases (8)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)

Interventions

Milnacipran (2)  ·  Cycloserine (1)  ·  Pregabalin (1)  ·  fremanezumab (1)

Sponsors

Forest Laboratories (2)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (2)  ·  Allergan (1)  ·  Boehringer Ingelheim (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)  ·  University of Calgary (1)

Countries

United States (7)  ·  Canada (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Patricia M D'Astoli, LPN (2)  ·  Alexander McGirr, MD, PhD (1)

Results publications

PMID 26112278, PMID 42162266